New York, NY, United States of America

Ralph E Kleiner

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 104(Granted Patents)


Location History:

  • Cambridge, MA (US) (2015)
  • New York, NY (US) (2016 - 2017)

Company Filing History:


Years Active: 2015-2017

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ralph E Kleiner: Innovator in Insulin-Degrading Enzyme Inhibitors

Introduction

Ralph E Kleiner is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of insulin-degrading enzyme inhibitors. With a total of 3 patents to his name, his work has the potential to impact the treatment of diabetes and related conditions.

Latest Patents

Kleiner's latest patents focus on macrocyclic insulin-degrading enzyme (IDE) inhibitors and their uses. These macrocyclic compounds specifically inhibit the insulin degrading enzyme (IDE). The patents describe pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, polymorphs, tautomers, isotopically enriched forms, and prodrugs of the macrocyclic IDE inhibitors. Additionally, pharmaceutical compositions are provided, along with in vivo and in vitro methods for using the IDE inhibitor. This includes applications for inhibiting IDE in subjects exhibiting aberrant IDE activity, impaired insulin signaling, or insulin resistance, particularly in individuals with diabetes.

Career Highlights

Ralph E Kleiner is associated with Harvard College, where he continues to advance his research and innovation in the field of biochemistry and pharmacology. His work is characterized by a commitment to developing solutions that address critical health issues.

Collaborations

Kleiner has collaborated with esteemed colleagues such as David R Liu and Juan Pablo Maianti. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the pharmaceutical industry.

Conclusion

Ralph E Kleiner's contributions to the field of insulin-degrading enzyme inhibitors exemplify the impact of innovative research on healthcare. His patents and ongoing work at Harvard College highlight the importance of scientific advancement in addressing diabetes and related health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…